Affiliation
Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: angela.lamarca@nhs.net. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA.Issue Date
2022
Metadata
Show full item recordAbstract
Management of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line 5-FU and oxaliplatin / irinotecan is the cornerstone of treatment for most patients in the absence of targetable alterations. Targeted therapies, including therapies for tumours with fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, Human epidermal growth factor-2 (HER-2) amplifications, and/ or microsatellite instability are rapidly changing the treatment paradigm for many patients with advanced BTC, especially for patients with intrahepatic cholangiocarcinoma. Because of this, molecular profiling should be considered early on patients pathway to allow adequate planning of therapy. Ongoing research is likely to clarify the role of immunotherapy, liver-directed therapy, and liver transplant for BTCs in the future.Citation
Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100378.Journal
ESMO OpenDOI
10.1016/j.esmoop.2021.100378PubMed ID
35032765Additional Links
https://dx.doi.org/10.1016/j.esmoop.2021.100378Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2021.100378
Scopus Count
Collections
Related articles
- Systemic treatment of advanced or recurrent biliary tract cancer.
- Authors: Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q
- Issue date: 2020 Nov 4
- Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
- Authors: Merters J, Lamarca A
- Issue date: 2023 Mar
- Targeted therapies in advanced biliary tract cancers-a narrative review.
- Authors: LaPelusa M, Heumann T, Goff L, Agarwal R
- Issue date: 2023 Apr
- Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
- Authors: Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I
- Issue date: 2020 Jun
- Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
- Authors: Neuzillet C, Artru P, Assenat E, Edeline J, Adhoute X, Sabourin JC, Turpin A, Coriat R, Malka D
- Issue date: 2023 Jan